Eli Lilly’s strategic emphasis on oral GLP-1 agonists and competing long-acting formulation partnerships has kept trader sentiment tilted toward “No” at 61.5% implied probability for a commercial license of Peptron’s SmartDepot microsphere technology by October 7, 2026. The original October 2024 evaluation agreement, extended through late 2026, remains in the research phase with no reported transition to binding technology transfer or licensing terms. Lilly’s April 2026 advancement of orforglipron and its 2025 Camurus collaboration for sustained-release peptides highlight a preference for internally developed or alternative delivery platforms, reducing urgency around Peptron’s injectable system. While Peptron continues joint peptide evaluation work, the absence of concrete licensing milestones or manufacturing commitments through early 2026 has reinforced market skepticism ahead of the resolution date.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডনতুন
নতুন
Oct 7, 2026
নতুন
নতুন
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s strategic emphasis on oral GLP-1 agonists and competing long-acting formulation partnerships has kept trader sentiment tilted toward “No” at 61.5% implied probability for a commercial license of Peptron’s SmartDepot microsphere technology by October 7, 2026. The original October 2024 evaluation agreement, extended through late 2026, remains in the research phase with no reported transition to binding technology transfer or licensing terms. Lilly’s April 2026 advancement of orforglipron and its 2025 Camurus collaboration for sustained-release peptides highlight a preference for internally developed or alternative delivery platforms, reducing urgency around Peptron’s injectable system. While Peptron continues joint peptide evaluation work, the absence of concrete licensing milestones or manufacturing commitments through early 2026 has reinforced market skepticism ahead of the resolution date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
মার্কেট ওপেন হয়েছে: May 5, 2026, 8:02 PM ET
ভলিউম
$8,224শেষ তারিখ
Oct 7, 2026মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s strategic emphasis on oral GLP-1 agonists and competing long-acting formulation partnerships has kept trader sentiment tilted toward “No” at 61.5% implied probability for a commercial license of Peptron’s SmartDepot microsphere technology by October 7, 2026. The original October 2024 evaluation agreement, extended through late 2026, remains in the research phase with no reported transition to binding technology transfer or licensing terms. Lilly’s April 2026 advancement of orforglipron and its 2025 Camurus collaboration for sustained-release peptides highlight a preference for internally developed or alternative delivery platforms, reducing urgency around Peptron’s injectable system. While Peptron continues joint peptide evaluation work, the absence of concrete licensing milestones or manufacturing commitments through early 2026 has reinforced market skepticism ahead of the resolution date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ভলিউম
$8,224শেষ তারিখ
Oct 7, 2026মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s strategic emphasis on oral GLP-1 agonists and competing long-acting formulation partnerships has kept trader sentiment tilted toward “No” at 61.5% implied probability for a commercial license of Peptron’s SmartDepot microsphere technology by October 7, 2026. The original October 2024 evaluation agreement, extended through late 2026, remains in the research phase with no reported transition to binding technology transfer or licensing terms. Lilly’s April 2026 advancement of orforglipron and its 2025 Camurus collaboration for sustained-release peptides highlight a preference for internally developed or alternative delivery platforms, reducing urgency around Peptron’s injectable system. While Peptron continues joint peptide evaluation work, the absence of concrete licensing milestones or manufacturing commitments through early 2026 has reinforced market skepticism ahead of the resolution date.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা